ES527027A0 - Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas - Google Patents

Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas

Info

Publication number
ES527027A0
ES527027A0 ES527027A ES527027A ES527027A0 ES 527027 A0 ES527027 A0 ES 527027A0 ES 527027 A ES527027 A ES 527027A ES 527027 A ES527027 A ES 527027A ES 527027 A0 ES527027 A0 ES 527027A0
Authority
ES
Spain
Prior art keywords
imidazolylalkylliten
tetrahydropyridazines
preparing
procedure
imidazolylalkylthienyltetrahydropyridazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES527027A
Other languages
English (en)
Spanish (es)
Other versions
ES8406472A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of ES8406472A1 publication Critical patent/ES8406472A1/es
Publication of ES527027A0 publication Critical patent/ES527027A0/es
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES527027A 1982-11-06 1983-11-04 Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas Granted ES527027A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823241102 DE3241102A1 (de) 1982-11-06 1982-11-06 Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
ES8406472A1 ES8406472A1 (es) 1984-07-01
ES527027A0 true ES527027A0 (es) 1984-07-01

Family

ID=6177509

Family Applications (1)

Application Number Title Priority Date Filing Date
ES527027A Granted ES527027A0 (es) 1982-11-06 1983-11-04 Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas

Country Status (11)

Country Link
US (1) US4643998A (https=)
EP (1) EP0112987B1 (https=)
JP (1) JPS59108781A (https=)
AT (1) ATE26274T1 (https=)
DE (2) DE3241102A1 (https=)
DK (1) DK156660C (https=)
ES (1) ES527027A0 (https=)
GR (1) GR78945B (https=)
IE (1) IE56127B1 (https=)
PT (1) PT77616B (https=)
ZA (1) ZA837976B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407509A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Neue arzneimittelkombination zur behandlung von bluthochdruck und thromboembolischen erkrankungen
DE3606105A1 (de) * 1986-02-26 1987-08-27 Nattermann A & Cie Verfahren zur herstellung von imidazolyl-thiophenaldehyden
DE3626865A1 (de) * 1986-08-08 1988-02-11 Boehringer Mannheim Gmbh Neue pyridazinon-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004036075B3 (de) * 2004-07-24 2006-02-16 Bos Gmbh & Co. Kg Anordnung für Seitenfensterrollo
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20180104220A1 (en) * 2015-04-24 2018-04-19 Medshine Discovery Inc. Imidazole compound
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
WO2018072702A1 (zh) * 2016-10-20 2018-04-26 南京明德新药研发股份有限公司 一种咪唑类化合物的晶型、盐型及其制备方法
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130252A1 (de) * 1981-07-31 1983-02-17 A. Nattermann & Cie GmbH, 5000 Köln 6-(5-((omega)-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydro-pyridazine und deren saeureadditionssalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
HU190412B (en) * 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) * 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones

Also Published As

Publication number Publication date
DK156660B (da) 1989-09-18
US4643998A (en) 1987-02-17
ATE26274T1 (de) 1987-04-15
DE3241102A1 (de) 1984-05-10
JPH054391B2 (https=) 1993-01-19
ES8406472A1 (es) 1984-07-01
DK156660C (da) 1990-03-05
PT77616B (en) 1986-03-19
EP0112987A1 (de) 1984-07-11
JPS59108781A (ja) 1984-06-23
GR78945B (https=) 1984-10-02
IE56127B1 (en) 1991-04-24
ZA837976B (en) 1984-06-27
DK505983A (da) 1984-05-07
IE832484L (en) 1984-05-06
PT77616A (en) 1983-12-01
DK505983D0 (da) 1983-11-04
DE3370626D1 (en) 1987-05-07
EP0112987B1 (de) 1987-04-01

Similar Documents

Publication Publication Date Title
ES527027A0 (es) Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas
ES524512A0 (es) Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos
ES525653A0 (es) Procedimiento para preparar nuevos diazabiciclo-(3.3.1)-nonanos
ES491224A0 (es) Procedimiento para la preparacion de anilidas de acidos 4- amino-2-ureido-(o-tioureido)-pirimidin-5-carboxilicos
NZ191867A (en) N1,n1,2,3,4,5,6-substituted-1-piperazine-carboxamides and carbothioamides
NO820686L (no) Fremgangsmaate ved fremstilling av nye aroylimidazoloner
ES485489A0 (es) Procedimiento para la preparacion de derivados de pirimido-(6,1-a)-isoquinolein-4-onas
ES8102561A1 (es) Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
ES521086A0 (es) Procedimiento para la preparacion de imidazolilfenil-tetrahidropiridazinas.
ES545155A0 (es) Procedimiento para la obtencion de (pirrol-1-il)-fenil-dihi-dropiridazinona
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
ES490069A0 (es) Procedimiento para la preparacion de derivados de amidas de acidos 1,2,3-tiadiazol-5-carboxilicos
IT1111538B (it) Procedimento per la fabbricazione di scambiatori di calore composti e relativi scambiatori
IL65936A (en) Chloroacetic acid cyclohexylamides,their preparation and their use as herbicides
ES530073A0 (es) Procedimiento para preparar la n-(3-trifluorometil fenil)-n-propargil-piperazina.
FI803305A7 (fi) Menetelmä uusien sulfonihapposykloalkyyliamidien valmistamiseksi ja niiden käyttö mikromikrobeja tuhoavina aineina.
ES508757A0 (es) "procedimiento para la preparacion de acidos antranilicos sustituidos con radicales basicos"
ES493419A0 (es) Procedimiento para la preparacion de cianuro de hidrogeno o acido cianhidrico
ATE28070T1 (de) N-(4-acetylaminophenacyl)-amino-derivate, ihre therapeutische verwendung und verfahren zu ihrer herstellung.
IT8009431A0 (it) Procedimento di sterilizzazione impiegante un coadiuvante dell'azione del calore

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506